IHH reports highest ever quarterly revenue in Q1 2024, with double-digit growth across key metrics, on outstanding performance across all markets
Highest ever quarterly revenue; revenue and EBITDA saw double-digit growth from sustained patient volume and taking on more acute, complex cases.
- Highest ever quarterly revenue; revenue and EBITDA saw double-digit growth from sustained patient volume and taking on more acute, complex cases.
- PATMI excluding exceptional items (“PATMI (ex EI)”) was up 22% on the strong operational performance.
- Balance sheet remained strong: net cash generated from operating activities at RM831.3 million; overall cash balance at RM2.2 billion.
- 1 The Group’s headline performance includes the application of the MFRS 129 accounting standard (Financial Reporting in Hyperinflationary Economies) relating to its entities in Türkiye.